Article

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-Trial

2023-01-25

Abstract excerpt

<h4>Background: </h4> In intermediate risk non-muscle-invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patients receive this adjuvant chemotherapeutic instillation. We recently developed a pipeline for the generation of patient derived organoids (PDO) in NMIBC. In t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4f73a41-27b1-575a-a8c3-5c2db1f51cfa
DOI: 10.21203/rs.3.rs-2497606/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialDOI 10.21203/rs.3.rs-2497606/v1Read

FOLLOW-U; study protocol evaluating oncological systemic treatment response of advanced bladder cancer patients using urinoidsSemantic proximity Read

Urine-derived bladder cancer organoids (urinoids) as tool for cancer longitudinal response monitoring and therapy adaptationSemantic proximity Read

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapiesSemantic proximity Read

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine ResponseSemantic proximity Read

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug ScreeningSemantic proximity Read

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read

BioBladder – a national longitudinal sampling study providing a comprehensive framework to precision oncology in urothelial cancerSemantic proximity Read

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read